Sick With Something That Isn ’ t COVID-19 or the Flu? Here ’ s What It Might Be
Flu season is wrapping up, and weekly COVID-19 diagnoses are declining. But if you’re currently sick with a respiratory illness, you’re not alone.
Data from the U.S. Centers for Disease Control and Prevention (CDC) show that a mixture of respiratory viruses are circulating right now, including common coronaviruses (other than SARS-CoV-2, which causes COVID-19), respiratory adenovirus, and parainfluenza (which is distinct from influenza).
All of these viruses can cause cold-like symptoms including fever, runny nose, sore throat, and cough, so “it’s very, very hard to tell the difference between any o...
Source: TIME: Health - March 20, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Disease healthscienceclimate Source Type: news
TREMFYA ® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis
SPRING HOUSE, PENNSYLVANIA, March 17, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA® (guselkumab) was associated with greater treatment persistencea compared to secukinumab or ixekizumab in bio-naïve and bio-experienced patientsb living with moderate to severe plaque psoriasis (PsO), based on pairwise analysesc of real-world data.[1],[2] Additionally, in a post-hoc analysis of Phase 3 VOYAGE 2 clinical trial results, TREMFYA demonstrated durable clinical efficacy, itch relief and quality-of-life improvements in patients living with scal...
Source: Johnson and Johnson - March 17, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Lower respiratory tract infection in early childhood linked with higher risk of dying from respiratory disease as an adult, study finds
Adults who had a lower respiratory tract infection such as bronchitis or pneumonia before the age of 2 may be at higher risk of dying prematurely from respiratory disease, according to a new study. Experts say the decades-long research may not directly apply to today's kids but shows how health effects can linger over a lifetime. (Source: CNN.com - Health)
Source: CNN.com - Health - March 8, 2023 Category: Consumer Health News Source Type: news
Respiratory infections in a child could lead to death as an adult: Study
The first-of-its-kind study spanning over seven decades suggests that people who had a lower-respiratory-tract infection (LRTI), such as bronchitis or pneumonia, by the age of two were 93% more likely to die prematurely from respiratory disease as adults, regardless of the socioeconomic background or the smoking status. (Source: The Economic Times)
Source: The Economic Times - March 8, 2023 Category: Consumer Health News Source Type: news
Late-Breaking Phase 3 A DUE Data Show Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Hemodynamics versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH)
RARITAN, NJ, March 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 3 A DUE study (NCT03904693), which showed an investigational once-daily, single tablet combination therapy, also known as fixed dose combination, of macitentan 10 mg and tadalafil 40 mg (M/T STCT), significantly improved pulmonary hemodynamics (blood flow through pulmonary blood vessels) versus macitentan and tadalafil monotherapies in pulmonary arterial hypertension (PAH) patients with World Health Organization (WHO) functional class (FC) II or III.[1] The data were presented today as a Late-...
Source: Johnson and Johnson - March 6, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
TREMFYA ® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
SPRING HOUSE, PENNSYLVANIA, March 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to support a hypothesis that not all IL-23 inhibitors are the same by demonstrating a differentiated binding mechanism for TREMFYA® (guselkumab) from risankizumab. Findings show that guselkumab is able to dose-dependently bind to CD64+a myeloid cells,1 the predominant source of IL-23-driven inflammation in the gut.2,b Data comprise one of Janssen’s 22 oral and poster presentations at the 18th Congress of the European Crohn’s and Col...
Source: Johnson and Johnson - March 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
' I Need Antibiotics for My Bronchitis,' Your Patient Insists'I Need Antibiotics for My Bronchitis,' Your Patient Insists
Do you capitulate and prescribe an antibiotic for"bronchitis" or is there an alternative?Medscape Family Medicine (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 23, 2023 Category: Allergy & Immunology Tags: Family Medicine/Primary Care Clinical Case Source Type: news
Severe Asthma Patients on Ways Their Doctors Could Improve Treatment
Approximately 25 million people in the U.S. have asthma, according to the Asthma and Allergy Foundation of America. While that number shows how common the condition has become, the severe form is more rare. An estimate from a September 2021 study in the Journal of Asthma and Allergy found that about 9% of people with asthma meet the criteria for severe asthma.
Severe asthma comes with significantly more challenges than regular asthma. People with this condition tend to experience more symptoms, including increased activity limitations, greater prevalence of heart disease, and lower lung function. Even with high doses of in...
Source: TIME: Health - February 7, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Disease healthscienceclimate Source Type: news
From dizziness to dry skin - 5 warning signs of conditions to spot in elderly relatives
Spotting these warning signs could help prevent a loved one suffering a serious health condition, such as a heart attack, hypothermia, flu, bronchitis or pneumonia. (Source: Daily Express - Health)
Source: Daily Express - Health - December 22, 2022 Category: Consumer Health News Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population
SPRING HOUSE, PENNSYLVANIA, November 11, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER program (DISCOVER-1 and DISCOVER-2) evaluating TREMFYA® (guselkumab) in adult patients with active psoriatic arthritis (PsA), which showed that early skin and enthesitis responsesa,b predicted longer-term clinical response,c including disease remission, at week 52.1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for adults with moderate to severe plaque psoriasis (PsO) and adults with active PsA...
Source: Johnson and Johnson - November 11, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life
SPRING HOUSE, PENNSYLVANIA, November 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER-2 study that show early (week 8) clinical improvementsa of most measures (joint and skin disease, enthesitis and dactylitis) in adult patients with active psoriatic arthritis (PsA) treated with TREMFYA® (guselkumab) were associated with meaningful improvements in health-related quality of life (HRQoL) (measured by EQ-5D)b from year one (week 52) through year two (week 100).1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor th...
Source: Johnson and Johnson - November 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Omicron: Bronchitis may persist 'for weeks' post-infection - three clues in your cough
Experts have warned that some symptoms of the latest Omicron strains are more likely to persist for weeks, compared to previous subvariants. (Source: Daily Express - Health)
Source: Daily Express - Health - November 7, 2022 Category: Consumer Health News Source Type: news
New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Lupin inks pact to acquire two inhalation brands from Sunovion for USD 75 mn
The acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the respiratory therapy area while continuing to provide patients access to these important medicines, Lupin said in a statement. Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2022 Category: Pharmaceuticals Source Type: news
